Killian Meara

At APhA 2024, 2 posters looked into how collaboration between physicians and community pharmacists is crucial when it comes to opioid prescriptions, and current opioid use patterns among older adults.

Two posters presented at APhA 2024 examined how the COVID-19 pandemic impacted pharmacists and their work.

Posters presented at the APhA 2024 Annual Meeting and Exposition discussed pharmacist barriers in pediatric immunizations, a novel meningococcal vaccine, and the need for inpatient reviews of vaccination history.

The Partnership for Safe Medicines found several product listings on Etsy that are designed to mimic regulated pharmaceuticals.

Jeffrey Reese, president at Reese Pharmaceutical, discusses what sets ColoTest apart from other at-home colorectal cancer screening tests.

Medication therapy management can also increase the likelihood of using statins in this population.

Results from a meta-analysis on the side of effects of the psychedelic psilocybin were presented at the 2024 American Pharmacists Association Annual Meeting & Exposition.

Rilpivirine (Edurant Ped) effectively suppresses the HIV-1 virus in pediatric patients with HIV-1 RNA less than or equal to 100,000 copies/mL in combination with other antiretroviral therapies.

Aprocitentan (TRYVIO) from pharmaceutical company Idorsia demonstrated statistically significant and clinically meaningful reductions in blood pressure in combination with other antihypertensive therapies.

The biotechnology company’s recombinant spike protein-based vaccine demonstrated an efficacy of 88% after 40 days, 82% after 120 days, and 77% after 180 days during the PREVENT-19 trial.

Despite the significant growth of biosimilars, their adoption across various therapeutic areas has remained slow.

The approval was based on data from the phase 1/2 TRANSCEND CLL 004 study, in which the CAR T cell therapy demonstrated statistically significant complete response rates.

The approval, awarded to Madrigal Pharmaceuticals, was based on phase 3 data demonstrating that resmetirom achieved broad treatment effects in patients with MASH with liver fibrosis.

With growing concerns around opioid use disorder, interventional pain management for patients with cancer can provide effective relief without the side effects associated with medication.

Cybin’s proprietary deuterated psilocybin analog, CYB003, provided robust and sustained improvements in depression symptoms in a phase 2 study.

A panel discussion at the Outcomes 2024 SYNC National Conference touched upon many important themes in community pharmacy, including the evolving role of pharmacists, emerging tech, and key challenges going forward.

Mind Medicine’s lysergide d-tartrate (MM120) demonstrated statistically significant and clinically meaningful improvements in anxiety symptoms in a phase 2b study.

The statement says the agency is talking with CMS to initiate new flexibilities, but multiple advocacy groups have said it’s not nearly enough.

Clobetasol propionate ophthalmic suspension 0.05% is the first ophthalmic clobetasol propionate product approved by the FDA and is the first new ophthalmic steroid on the market in over 15 years.

Viking Therapeutics’ VK2735 met both of its primary and secondary endpoints in the VENTURE trial, demonstrating statistically significant reductions in body weight compared to placebo.

Analysis of participants who never used tobacco cigarettes showed that daily cannabis use was associated a higher risk of both heart attack and stroke.

Reese Pharmaceutical’s ColoTest has a suggested retail price of $19.99 and will also be sold on major retail shelves later this spring.

Participants of a recent study who received automated text messaging and monitoring, as well as peer support and coaching, increased PrEP uptake from 11% to over 20%.

Pacience Edwards, PharmD, manager of compliance at Outcomes, discussed during a session at Outcomes 2024 SYNC National Conference several specific opportunities at the pharmacists disposal.

Nicole Bernabe, CPhT, customer success specialist at TelePharm, discusses how the company is helping pharmacies increase operational efficiency while providing care to patients in need.

During a session at the Outcomes 2024 SYNC National Conference, Pacience Edwards, PharmD, manager of compliance at Outcomes, discussed the impacts that advancements in technology have had on pharmacy.

Pacience Edwards, PharmD, manager of compliance at Outcomes, discussed how technological solutions can aid pharmacies during a session at the Outcomes 2024 SYNC National Conference in Orlando, Florida.

The approval was based on positive data from a phase 3 trial that showed patients treated with omalizumab were significantly more likely to tolerate peanut, milk, egg, or cashew protein without moderate to severe allergic symptoms.

As pharmacies continue their rapid adoption of technological tools to improve efficiency, being prepared for cyberattacks is more important than ever.

Drug Topics sat down with Jude Dieterman, CEO of Outcomes, to discuss the value and uniqueness of the company in the pharmacy market, what’s next on the horizon, and the upcoming event.